AMAG Reports Fourth Quarter and Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
AMAG Pharmaceuticals (AMAG) PT Lowered to $40 at Jefferies; Reiterates Buy
February 15, 2017 8:07 AM ESTJefferies lowered its price target on AMAG Pharmaceuticals (NASDAQ: AMAG) to $40.00 (from $45.00) while maintaining a Buy rating.
Analyst Eun Yang commented, "No surprise vs. pre-announced 4Q16 results on 1/9/17. Another acquisition of women's health product Intrarosa also fails to excite investors (following Rekynda on 1/9/17).... More
AMAG Pharma (AMAG) Reports Q4 Loss of $0.31
February 14, 2017 7:05 AM ESTAMAG Pharma (NASDAQ: AMAG) reported Q4 EPS of ($0.31), versus $0.20 reported last year. Revenue for the quarter came in at $151.6 million versus the consensus estimate of $153.25 million.
"We drove significant top- and bottom-line growth in 2016, building an even stronger base to grow and... More
